⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 23, 2024JAMA Oncology

Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease

Kamran A. Ahmed Priya Kumthekar Yolanda Piña Youngchul Kim Michael A. Vogelbaum Hyo S. Han Peter Forsyth

View Full Paper

Ask AI

Bookmark

Share

Abstract

This nonrandomized controlled trial examines the safety of radiation therapy (RT) followed by intrathecal trastuzumab and pertuzumab for patients with ERBB2-positive breast leptomeningeal disease (LMD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ahmed et al. (2024) studied this question.

synapsesocial.com/papers/68e68ab9b6db643587612cde https://doi.org/10.1001/jamaoncol.2024.1299

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1OCTS-07 TRIAL IN PROGRESS: PHASE II STUDY OF RADIATION THERAPY FOLLOWED BY INTRATHECAL TRASTUZUMAB/PERTUZUMAB IN THE MANAGEMENT OF HER2+ BREAST LEPTOMENINGEAL DISEASE2024 · 2 citations
2Abstract PD13-08: Radiation Therapy Followed by Intrathecal (IT) Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease: Interim Results from a Phase II Multi-Institutional StudyHuman Clinical Trial · 2026
3A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokineticsEarly-Phase Clinical Trial · 2022 · 87 citations
4Trastuzumab-deruxtecan for the management of leptomeningeal metastases from breast cancer.Review · 2026
5NCOG-60. Trastuzumab-deruxtecan for the management of leptomeningeal metastases from breast cancer2025